A Novel Nutrient Mixture Exhibits Antitumor Activity In Human Fibrosarcoma Cell Line Ht-1080

Proceedings: AACR 102nd Annual Meeting 2011‐‐ Apr 2‐6, 2011; Orlando, FL Introduction: Fibrosarcoma, an aggressive and highly metastatic cancer of connective tissue, is generally associated with poor prognosis. Cancer mortality usually results from tumor invasion of local tissue and metastasis to vital organs. We investigated the effect of a specific nutrient mixture (PB) of quercetin, cruciferex, curcumin, green tea extract and resveratrol on human fibrosarcoma cell line HT-1080 for viability, MMP expression, invasion, apoptosis and morphology. Material and Methods: Human fibrosarcoma cell line HT-1080 (ATCC) was cultured in DEM media, supplemented with 10% FBS and antibiotics in 24-well tissue plates. At near confluence, cells were treated with PB at 0, 10, 25, 50, 75 and 100 mcg/mL, in triplicate at each dose. Cells were also treated with PMA (100 ng/mL) for MMP-9 induction. Cell proliferation was assayed by MTT assay, MMP by zymography, invasion through Matrigel, apoptosis using green caspase detection, and morphology by H&E staining. Results: PB inhibited proliferation of human fibrosarcoma cells HT-1080 by 50% at 10 mcg/mL, 60% at 25 mcg/mL and 80% at 50-100 mcg/mL, and inhibited the secretion of both MMP-2 and MMP-9 in a dose-dependent manner, with total inhibition at 50 mcg/mL concentration. Invasion through Matrigel was inhibited 100% at 25 mcg/mL PB. PB also induced apoptosis in a dose- dependent fashion. H&E staining showed slight morphological changes at higher concentrations. Conclusion: These results suggest that PB is a potential therapeutic agent for fibrosarcoma, with potent anti-metastatic activity, because it inhibited fibrosarcoma cell proliferation, MMP-2 and -9 expression, invasion through Matrigel and apoptosis, important parameters for cancer prevention. Citation Format: {Authors}. {Abstract title} [abstract]. In: Proceedings of the 102nd Annual Meeting of the American Association for Cancer Research; 2011 Apr 2-6; Orlando, FL. Philadelphia (PA): AACR; Cancer Res 2011;71(8 Suppl):Abstract nr 1500. doi:10.1158/1538-7445.AM2011-1500